Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 1,004,078 | 995,830 | 994,227 | 1,004,852 | 1,032,135 |
| Cost of Goods | 640,704 | 701,166 | 684,543 | 666,060 | 675,068 |
| Gross Profit | 363,374 | 294,664 | 309,684 | 338,792 | 357,067 |
| Operating Expenses | 244,190 | 174,933 | 593,667 | 205,053 | 257,001 |
| Operating Income | 119,888 | 119,897 | -283,440 | 133,799 | 100,134 |
| Interest Expense | 30,340 | 26,742 | 23,775 | 25,403 | 29,967 |
| Other Income | -36,378 | -123,097 | 13,116 | -21,196 | 1,251 |
| Pre-tax Income | 53,170 | -29,942 | -294,099 | 87,200 | 71,418 |
| Income Tax | 53,930 | -15,140 | -17,809 | 31,644 | 18,725 |
| Net Income Continuous | -760 | -14,802 | -276,290 | 55,556 | 52,693 |
| Minority Interests | 722 | 41 | 265 | 1,134 | 367 |
| Net Income | $-1,482 | $-14,843 | $-276,555 | $54,422 | $52,326 |
| EPS Basic Total Ops | -0.03 | -0.30 | -5.58 | 1.11 | 1.06 |
| EPS Basic Continuous Ops | -0.02 | -0.30 | -5.58 | 1.13 | 1.07 |
| EPS Diluted Total Ops | -0.03 | -0.30 | -5.57 | 1.10 | 1.06 |
| EPS Diluted Continuous Ops | -0.02 | -0.30 | -5.57 | 1.12 | 1.07 |
| EPS Diluted Before Non-Recurring Items | N/A | 2.06 | 2.39 | 2.43 | 3.12 |
| EBITDA(a) | $187,178 | $187,048 | $-40,163 | $218,963 | $219,641 |